Weijing Biomedical Technology

Weijing Biomedical Technology is a Shanghai-based biotechnology company specializing in the development of next-generation gene therapies using proprietary Adeno-associated virus (AAV) technology. The company leverages an advanced AAV capsid engineering and directed evolution platform to create delivery vectors with enhanced tissue tropism, improved efficiency, and reduced immunogenicity. Their therapeutic pipeline primarily targets high-unmet-need conditions within the central nervous system (CNS) and ophthalmology, with lead programs currently in the pre-clinical and IND-enabling stages. Weijing Bio has established internal GMP manufacturing capabilities to support its clinical development and is backed by prominent venture capital firms including Sequoia China and Lilly Asia Ventures.